Solid forms of encukalner and process for the preparation thereof
The novel crystalline Form-Dl of Encukalner and amorphous solid dispersions address the solubility and stability challenges of existing forms by utilizing specific excipients and preparation methods, enhancing solubility and stability for pharmaceutical use.
Patent Information
- Application Number
- PCT/IN2026/050747
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Existing crystalline forms of Encukalner exhibit reduced solubility and stability under physiological conditions, and amorphous forms are thermodynamically unstable, necessitating the development of a form with improved solubility and stability for pharmaceutical applications.
The development of amorphous solid dispersions and a novel crystalline Form-Dl of Encukalner, characterized by specific PXRD patterns and prepared using various pharmaceutically acceptable excipients such as HPMC, PVP, and Soluplus, along with controlled solvent stirring and drying processes.
The crystalline Form-Dl exhibits enhanced solubility and stability, maintaining physical and chemical integrity under simulated physiological conditions, and the amorphous solid dispersions provide improved solubility profiles.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000013_0001_TABLE 
Figure IMGF000013_0002_TABLE
Abstract
Description
[0001] SOLID FORMS OF ENCUKALNER AND PROCESS FOR THE PREPARATION THEREOF
[0002] CROSS REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of Indian provisional patent application No. 202541043194 filed on 5 May 2025.
[0004] FIELD OF THE INVENTION
[0005] The present invention relates to amorphous solid dispersions and a novel anhydrous crystalline Form-Dl of Encukalner, and process for the preparation thereof.
[0006] BACKGROUND OF THE INVENTION
[0007] Encukalner is chemically known as N-[4-(6-fluoro-3,4-dihydro-lH-isoquinolin-2-yl)-2,6- dimethylphenyl]-3,3-dimethylbutanamide and is represented by a compound of structural formula I as mentioned below
[0008]
[0009] Formula I
[0010] Encukalner is being studied for its potential as a treatment for refractory focal onset seizures and major depressive disorder.
[0011] The PCT publication W02021072307 discloses Crystalline Form 1, Form 2, Form 3, Form 4, Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, Form 11 and amorphous form for Encukalner free base.
[0012] Polymorphism is the occurrence of different crystalline forms of a single compound and it is a property of some compounds and complexes. Thus, polymorphs are distinct solids sharing the same molecular formula, yet each polymorph may have distinct physical properties. Therefore, a single compound may give rise to a variety of polymorphic forms where eachform has different and distinct physical properties, such as different solubility profiles, different melting point temperatures and / or different x-ray diffraction peaks.
[0013] Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as, differential scanning calorimetry. Additionally, polymorphic forms of the same drug substance or active pharmaceutical ingredient, can be administered by itself or formulated as a drug product and are well known in the pharmaceutical art to affect, for example, the solubility, stability, flowability, tractability and compressibility of drug substances and the safety and efficacy of drug products.
[0014] Encukalner is known to exist in multiple crystalline forms exhibiting different physicochemical properties such as solubility, stability etc. The PCT publication W02021072307 has disclosed several polymorphic forms of Encukalner. However, known crystalline forms exhibit limitations, including reduced solubility under physiological conditions and stability challenges during processing and storage. Amorphous drug forms tend to be unstable. As amorphous forms are thermodynamically unstable relative to the corresponding crystal forms, the amorphous form would convert back to the stable crystalline form.
[0015] Hence, there was a need to develop crystalline form with improved solubility and stability to meet the requirements of pharmaceuticals finished product.
[0016] SUMMARY OF THE INVENTION
[0017] The present invention provides amorphous solid dispersion and crystalline form of Encukalner and process for preparation thereof.
[0018] First aspect of the present invention provides crystalline Form-Dl of Encukalner characterized by its powder X-ray diffraction (PXRD) pattern having peaks at about 5.64, 6.73, 7.08, 10.38, 11.19, 11.51, 13.57, 14.91, 15.45, 16.48, 18.79, 19.99, 20.46 and 21.89 ±0.2° 20;
[0019] In an aspect the present invention provides crystalline Form-Dl of Encukalner further characterized by its powder X-ray diffraction (PXRD) pattern having peaks at about 9.33,12.19, 12.87, 14.39, 15.3, 17.35, 18.17, 19.07, 20.74, 21.11, 22.56, 23.4, 23.78, 25.44, 25.75 and 27.35± 0.2° 20.
[0020] Second aspect of the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carrier.
[0021] Third aspect of the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carriers wherein excipient / carrier is selected from hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), co-povidone, hydroxypropyl cellulose, carboxymethylcellulose (CMC), ethyl cellulose, polyethylene glycol (PEG), Soluplus, methacrylic acid or a mixture thereof.
[0022] Fourth aspect of the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carrier wherein the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1:1 to about 1:5 w / w, more particularly the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1:1 to about 1:4 w / w.
[0023] Fifth aspect of the present invention provides amorphous solid dispersion of Encukalner with PVP K-30.
[0024] Sixth aspect of the present invention provides amorphous solid dispersion of Encukalner with HPMC E5.
[0025] Seventh aspect of the present invention provides amorphous solid dispersion of Encukalner with Copovidone.
[0026] Eighth aspect of the present invention provides amorphous solid dispersion of Encukalner with Soluplus.Ninth aspect of the present invention provides crystalline Form-Dl of Encukalner characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 5.
[0027] Tenth aspect of the present application provides a process for preparing crystalline Form-Dl of Encukalner; the process comprising;
[0028] a) Providing a solution of Encukalner in a suitable solvent;
[0029] b) Stirring at about 60 °C to about 80 °C
[0030] c) Cooling and isolating the crystalline Form-Dl
[0031] Eleventh aspect of the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with PVP K-30; the process comprising;
[0032] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of PVP K-30
[0033] c) drying the clear solution to obtain amorphous solid dispersion;
[0034] Twelfth aspect of the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with HPMC E5; the process comprising;
[0035] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of HPMC E5
[0036] c) drying the clear solution to obtain amorphous solid dispersion;
[0037] Thirteenth aspect of the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with Copovidone; the process comprising;
[0038] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of Copovidone
[0039] c) drying the clear solution to obtain amorphous solid dispersion;
[0040] Fourteenth aspect of the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with Soluplus; the process comprising;
[0041] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of Soluplus
[0042] c) drying the clear solution to obtain amorphous solid dispersion;Fifteenth aspect of the present invention provides Encukalner having a purity of greater than or equal to 99% w / w.
[0043] Sixteenth aspect of the present invention provides a pharmaceutical composition comprising amorphous solid dispersion of Encukalner with PVP K-30; amorphous solid dispersion of Encukalner with HPMC E5; amorphous solid dispersion of Encukalner with Copovidone; amorphous solid dispersion of Encukalner with Soluplus; anhydrous crystalline Form-Dl of Encukalner and at least one pharmaceutically acceptable carrier.
[0044] BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 is powder X-ray diffraction ("PXRD") pattern of Encukalner ASD with API: PVP K-30.
[0046] Figure 2 is powder X-ray diffraction ("PXRD") pattern of Encukalner ASD with API: HPMC E5.
[0047] Figure 3 is powder X-ray diffraction ("PXRD") pattern of Encukalner ASD with API: Copovidone.
[0048] Figure 4 is powder X-ray diffraction ("PXRD") pattern of Encukalner ASD with API: Soluplus.
[0049] Figure 5 is powder X-ray diffraction ("PXRD") pattern of anhydrous crystalline form-Dl of Encukalner.
[0050] Figure 6 is Differential scanning calorimetry ("DSC") thermogram of anhydrous crystalline Form-Dl of Encukalner.
[0051] Figure 7 is Thermogravimetric analysis ("TGA") of anhydrous crystalline Form-Dl of Encukalner.
[0052] Figure 8 is a Dynamic vapour sorption (DVS) of anhydrous crystalline Form-Dl of Encukalner.
[0053] Figure 9 is a PXRD comparison of standard anhydrous crystalline Form-Dl with Post DVS PXRD of anhydrous crystalline Form-Dl of Encukalner.
[0054] Figure 10 is a Fourier Transform Infrared (FTIR) spectrum comparison of anhydrous crystalline Form-Dl of Encukalner with crystalline Form-2, Form-3 and Form-4.Figure 11 is a Raman spectroscopic analysis comparison of anhydrous crystalline Form-Dl of Encukalner with crystalline Form-2, Form-3 and Form-4.
[0055] DETAILED DESCRIPTION OF THE INVENTION
[0056] The present invention provides amorphous solid dispersion and novel crystalline form of Encukalner and process for preparation thereof.
[0057] In one embodiment, the present invention provides crystalline form-Dl of Encukalner.
[0058] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by its powder X-ray diffraction (PXRD) pattern having peaks at about 5.64, 6.73, 7.08, 10.38, 11.19, 11.51, 13.57, 14.91, 15.45, 16.48, 18.79, 19.99, 20.46 and 21.89 ±0.2° 20;
[0059] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner further characterized by its powder X-ray diffraction (PXRD) pattern having peaks at about 9.33, 12.19, 12.87, 14.39, 15.3, 17.35, 18.17, 19.07, 20.74, 21.11, 22.56, 23.4, 23.78, 25.44, 25.75 and 27.35± 0.2° 20.
[0060] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 5.
[0061] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a differential scanning calorimetry (DSC) wherein crystalline Form-Dl exhibits an endothermic peak temperature at about 188 ±2 °C and endothermic onset temperature at about 185 ±2 °C.
[0062] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a differential scanning calorimetry (DSC) substantially as illustrated in Figure 6.In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a thermogravimetric analysis (TGA) wherein crystalline Form-Dl indicated a total weight loss of about 1.05 % from ambient temperature to about 200 °C indicating that the crystalline Form-Dl is substantially non-solvated and thermally stable.
[0063] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a thermogravimetric analysis (TGA) substantially as illustrated in Figure 7.
[0064] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a Dynamic vapour sorption (DVS) analysis by increasing and decreasing relative humidity (RH) steps, ranging from 0% to about 90% RH, at a constant temperature indicated a weight change of 0.063% at 80% RH indicating that the crystalline Form-Dl is Non-hygroscopic and suitable for pharmaceutical development, manufacturing, and storage of finished dosage form.
[0065] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by a Dynamic vapour sorption (DVS) substantially as illustrated in Figure 8.
[0066] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by Fourier Transform Infrared (FTIR) spectrum comprising absorption peaks at 2828, 859, 829, 821, 802, 730, 710, 533, 472, and 453 ±5 cm-1.
[0067] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by Fourier Transform Infrared (FTIR) spectrum comparison of crystalline Form-Dl with crystalline Form-2, Form-3 and Form-4 substantially as illustrated in Figure 10.
[0068] In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by Raman spectrum comprising peak positions at 211, 235, 969, 1030, 1237, 1263, 1298, 2904, 2920, 3053 and 3868±5 cm-1.In one embodiment, the present invention provides crystalline Form-Dl of Encukalner characterized by Raman spectroscopic analysis comparison of crystalline Form-Dl of Encukalner with crystalline Form-2, Form-3 and Form-4 substantially as illustrated in Figure 11.
[0069] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carrier.
[0070] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carriers wherein excipient / carrier is selected from hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), co-povidone, hydroxypropyl cellulose, carboxymethylcellulose (CMC), ethyl cellulose, polyethylene glycol (PEG), Soluplus, methacrylic acid or a mixture thereof.
[0071] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with at least one pharmaceutically acceptable excipient / carrier wherein the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1:1 to about 1:5 w / w, more particularly the ratio of Encukalner to the pharmaceutically acceptable excipient / carrier is about 1 : 1 to about 1 :4 w / w.
[0072] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with PVP K-30.
[0073] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with PVP K-30 wherein the ratio of Encukalner with PVP K-30 is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner with PVP K-30 is about 1:1 to 1:5 w / w, more particularly the ratio of Encukalner with PVP K-30 is about 1:1 to 1:4 w / w.
[0074] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with PVP K-30 characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 1.In one embodiment, of the present invention provides amorphous solid dispersion of Encukalner with HPMC E5.
[0075] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with HPMC E5 wherein the ratio of Encukalner with HPMC E5 is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner with HPMC E5 is about 1:1 to 1:5 w / w, more particularly the ratio of Encukalner with HPMC E5 is about 1:1 to 1:4 w / w.
[0076] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with HPMC E5 characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 2.
[0077] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Copovidone.
[0078] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Copovidone wherein the ratio of Encukalner with Copovidone is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner with Copovidone is about 1:1 to 1:5 w / w, more particularly the ratio of Encukalner with Copovidone is about 1:1 to 1:4 w / w.
[0079] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Copovidone characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 3.
[0080] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Soluplus.
[0081] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Soluplus wherein the ratio of Encukalner with Soluplus is about 1:1 to 1:10 w / w, particularly the ratio of Encukalner with Soluplus is about 1:1 to 1:5 w / w, more particularly the ratio of Encukalner with Soluplus is about 1:1 to 1:4 w / w.
[0082] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner with Soluplus characterized by its powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 4.In one embodiment, present application provides a process for preparing crystalline Form-Dl of Encukalner; the process comprising;
[0083] a) Providing a solution of Encukalner in a suitable solvent;
[0084] b) Stirring at about 60 °C to about 80 °C
[0085] c) Cooling and isolating the crystalline Form-Dl
[0086] The suitable solvent used in step a) for preparing crystalline Form-Dl of Encukalner is selected from the group comprising esters, ethers, hydrocarbon solvents or mixture thereof. The solvent used in step a) for preparing crystalline Form-Dl of Encukalner is an ester solvent selected from the group comprising ethyl acetate, isopropyl acetate, butyl acetate and / or mixture thereof.
[0087] The solvent used in step a) for preparing crystalline Form-Dl of Encukalner is an ether solvent preferably nonpolar ether solvent selected from the group comprising 1,4-dioxane, diethyl ether, tetrahydrofuran and / or mixture thereof.
[0088] The solvent used in step a) for preparing crystalline Form-Dl of Encukalner is a hydrocarbon solvent selected from the group comprising hexane, heptane, toluene, xylene, ethylbenzene and / or mixture thereof.
[0089] In one embodiment the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with PVP K-30; the process comprising;
[0090] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of PVP K-30
[0091] c) drying the clear solution to obtain amorphous solid dispersion;
[0092] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with PVP K-30 is selected from the group comprising alcohol, ketone, hydrocarbon, ester solvents or mixture thereof.
[0093] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with PVP K-30 is an alcohol solvent selected from the group comprising methanol, ethanol isopropyl alcohol, butyl alcohol and / or mixture thereof.
[0094] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with PVP K-30 is a ketone solvent selected from the group comprising acetone, butanone, Methyl isobutyl ketone, Methyl isopropyl ketone, pentanone and / or mixture thereof.The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with PVP K-30 is an ester solvent selected from the group comprising ethyl acetate, isopropyl acetate, butyl acetate and / or mixture thereof.
[0095] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with PVP K-30 is a hydrocarbon solvent selected from the group comprising hexane, heptane, toluene, xylene, ethylbenzene and / or mixture thereof.
[0096] In one embodiment, the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with HPMC E5; the process comprising;
[0097] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of HPMC E5
[0098] c) drying the clear solution to obtain amorphous solid dispersion;
[0099] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with HPMC E5 is selected from the group comprising alcohol, ketone, hydrocarbon, ester solvents or mixture thereof.
[0100] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with HPMC E5 is an alcohol solvent selected from the group comprising methanol, ethanol isopropyl alcohol, butyl alcohol and / or mixture thereof.
[0101] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with HPMC E5 is a ketone solvent selected from the group comprising acetone, butanone, Methyl isobutyl ketone, Methyl isopropyl ketone, pentanone and / or mixture thereof.
[0102] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with HPMC E5 is an ester solvent selected from the group comprising ethyl acetate, isopropyl acetate, butyl acetate and / or mixture thereof.
[0103] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with HPMC E5 is a hydrocarbon solvent selected from the group comprising hexane, heptane, toluene, xylene, ethylbenzene, dichloromethane and / or mixture thereof.
[0104] In one embodiment, the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with Copovidone; the process comprising;
[0105] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of Copovidonec) drying the clear solution to obtain amorphous solid dispersion;
[0106] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Copovidone is selected from the group comprising alcohol, ketone, hydrocarbon, ester solvents or mixture thereof.
[0107] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Copovidone is an alcohol solvent selected from the group comprising methanol, ethanol isopropyl alcohol, butyl alcohol and / or mixture thereof.
[0108] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Copovidone is a ketone solvent selected from the group comprising acetone, butanone, Methyl isobutyl ketone, Methyl isopropyl ketone, pentanone and / or mixture thereof.
[0109] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Copovidone is an ester solvent selected from the group comprising ethyl acetate, isopropyl acetate, butyl acetate and / or mixture thereof.
[0110] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Copovidone is a hydrocarbon solvent selected from the group comprising hexane, heptane, toluene, xylene, ethylbenzene and / or mixture thereof.
[0111] In one embodiment, the present invention relates to a process for preparing amorphous solid dispersion of Encukalner with Soluplus; the process comprising;
[0112] a) Providing a solution of Encukalner in a suitable solvent or mixture of solvents; b) adding a solution of Soluplus
[0113] c) drying the clear solution to obtain amorphous solid dispersion;
[0114] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Soluplus is selected from the group comprising alcohol, ketone, hydrocarbon, ester solvents or mixture thereof.
[0115] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Soluplus is an alcohol solvent selected from the group comprising methanol, ethanol isopropyl alcohol, butyl alcohol and / or mixture thereof.
[0116] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Soluplus is a ketone solvent selected from the group comprising acetone, butanone, Methyl isobutyl ketone, Methyl isopropyl ketone, pentanone and / or mixture thereof.The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Soluplus is an ester solvent selected from the group comprising ethyl acetate, isopropyl acetate, butyl acetate and / or mixture thereof.
[0117] The solvent as mentioned in step a) for preparing amorphous solid dispersion of Encukalner with Soluplus is a hydrocarbon solvent selected from the group comprising hexane, heptane, toluene, xylene, ethylbenzene and / or mixture thereof.
[0118] In an embodiment, the physical and chemical stability of crystalline Form-Dl of Encukalner was determined by storing the samples at 2-8°C, 25°C / 60% relative humidity (RH) and 40°C / 75% relative humidity (RH) conditions for one and three months and the samples were analyzed by PXRD and purity by HPLC. The results are shown in below Table 1. Crystalline Form-Dl of Encukalner was found to be physically and chemically stable at 2-8°C and at 25°C and 60% relative humidity (RH) conditions and 40°C and 75% relative humidity (RH) conditions up to three months.
[0119] Table 1
[0120] Initial material Time Condition
[0121] evaluation (month)
[0122] FormType of Stability in Stability in Stability in Name form 2-8°C 25°C; 60% 40°C; 75% RH (closed) RH (closed)
[0123] (closed)
[0124] PXRD Purity (%) PXRD Purity PXRD Purity PXRD Purity Form- Form- Form- 1 98.57 98.68 98.63 Form- Dl Dl Dl Anhydrous
[0125] Dl Form-Dl 98.86
[0126] Form- Form- Form- 3 Dl 98.54 Dl 98.53 Dl 98.45
[0127]
[0128] In an embodiment, the stress data of crystalline form-Dl of Encukalner was determined by storing the samples at 80% relative humidity (RH) conditions for four days and the samples were analyzed by PXRD and purity by HPLC. The results are shown in below Table 2.
[0129] Table 2
[0130] Forms Initial material evaluation Exposure to 80%RH 4 days open
[0131]
[0132] PXRD Purity (%) PXRD Purity Form-Dl Form-Dl 98.86 Form-Dl 99.30
[0133]
[0134] In an embodiment, the solubility comparison of Encukalner crystalline form-Dl and other crystalline forms of Encukalner including Form-2, Form-3 and Form-4 was determined in pH 1.2 buffer at 37 ±2°C in order to simulate physiological gastric conditions at defined time intervals of 30 minutes and 1 hour. The study was conducted both in the absence and in the presence of polysorbate- 80 a non-ionic surfactant at a concentration of 0.1% w / v, to assess the intrinsic solubility characteristics of the crystalline forms. The results are shown in below Table 3.
[0135] Table 3
[0136] pH 1.2
[0137] Polysorbate 80 added to buffer at 0.1% No polysorbate 80 added to buffer Form w / v solution
[0138] Solubility (pg / mL) Solubility (jig / mL)
[0139] 30 min 1 h 30 min 1 h Form- ___ ___ 466 424 Dl
[0140] Form-2 29 34 2 5 Form- 3 307 370 70 108 Form -4 ___ ___ 163 195
[0141]
[0142] Based on above results Encukalner crystalline form-Dl consistently demonstrate 2.5 to 3 times the higher solubility as compared with the reported crystalline Form 4 in the absence of polysorbate- 80 in pH 1.2 buffer at 37 ±2°C. This shows Encukalner crystalline form-Dl is distinct, higher-solubility crystalline form with improved gastric dissolution.
[0143] In an embodiment, the solubility comparison of Encukalner crystalline form-Dl and other crystalline forms of Encukalner including Form-2, Form-3 and Form-4 was determined in pH 6.8 buffer at 37 ±2°C in order to simulate physiological intestinal fluid conditions at definedtime intervals of 1 hour and 2 hour. The study was conducted both in the absence and in the presence of polysorbate- 80 a non-ionic surfactant at a concentration of 0.1% w / v, to assess the intrinsic solubility characteristics of the crystalline forms. The results are shown in below Table 4.
[0144] Table 4
[0145] pH 6.8
[0146] Polysorbate 80 added to buffer to No polysorbate 80 added to buffer Form prepare 0.1% w / v solution
[0147] Solubility (pg / mL) Solubility (pg / mL)
[0148] 1 h 2h 1 h 2h Form- ___ ___ Below LOQ Below LOQ Dl
[0149] Form-2 6 7 Below LOQ Below LOQ Form- 3 5 6 Below LOQ Below LOQ Form-4 ___ ___ Below LOQ Below LOQ
[0150]
[0151] *LOQ (Limit of Quantification)
[0152] Based on above results Encukalner crystalline form-Dl and reported crystalline Form 4 exhibited solubility below the limit of quantification (LOQ) at pH 6.8 buffer at 37 ±2°C irrespective of presence of polysorbate-80. This indicates that neither Encukalner anhydrous crystalline Form-Dl nor other reported crystalline forms possess appreciable intrinsic solubility under intestinal pH conditions.
[0153] In an embodiment, solid state stability of crystalline form DI of Encukalner is assessed during representative pharmaceutical manufacturing operations, such as wet granulation, drying, and direct compression. X-ray diffraction (XRD) and purity analysis were performed on crystalline form DI of Encukalner as such. Subsequently, a weighed quantity of the DI form was subjected to manual wet granulation by sprinkling water, followed by drying in a hot air oven at 60 °C for 2 hours. Post-drying, XRD and purity analysis were performed to evaluate any changes induced on exposure to water during the wet granulation process, Additionally, a weighed quantity of the DI form was compressed as such using compressionmachine, and subjected to XRD and purity analysis. These results were compared with the initial data to assess any changes arising from direct compression or wet granulation followed by drying process. The results are shown in below Table 5.
[0154] Table 5
[0155] Wet mass prep followed by Drying Compaction Molecule Purity
[0156] Type of form
[0157] name XRD After XRD Initial treatment
[0158] Crystalline form No change after No change after Encukalner
[0159] DI treatment 98.86 98.7 treatment
[0160]
[0161] Based on above results there is no change in solid state and purity of Crystalline Form DI of Encukalner after exposure to above pharmaceutical processing steps.
[0162] In an embodiment, any physical form of Encukalner may be used as input material for slurry experiments of the present invention.
[0163] Suitable techniques that may be used for the isolation of Encukalner of the present invention include but not limited to filtration, decantation, solvent evaporation using flash evaporation, simple evaporation, rotational drying such as drying using a rotavapor, spray drying, agitated thin-film drying, freeze -drying or any other technique known in the art.
[0164] In some embodiments, isolated compounds of the present invention may optionally be further dried. Drying can be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying can be carried out at temperatures of less than about 75 °C, less than about 50°C, or any other suitable temperatures; at atmospheric pressure or under a reduced pressure; as long as the product is not degraded in its quality. The drying can be carried out for any desired time until the required product quality is achieved. Suitable time for drying can vary from few minutes to several hours for example from about 30 minutes to about 24 or more hours.In an embodiment, the compounds of the present invention may be purified by any method known in the art such as chromatographic purification, crystallization, acid-base salt formation and the like using suitable solvents. Suitable solvent include but not limited to aliphatic hydrocarbon solvent such as hexane, heptane and the like; alcohol solvent but not limited to methanol, ethanol, isopropanol and the like; aromatic hydrocarbon solvent such as toluene, xylene and the like; ketone solvent such as acetone, ethyl methyl ketone and the like; ether solvents such as diethyl ether, methyl t-butyl ether, tetrahydrofuran and the like; ester solvent such as ethyl acetate, isopropyl acetate and the like; nitrile solvents such as acetonitrile, propionitrile and the like; chlorinated solvent such as dichloromethane, chloroform and the like; polar aprotic solvents such as DMF, DMSO, DMAc; water; and mixtures thereof. The resulting compound obtained in step (c) may optionally be further dried. Drying can be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying can be carried out at temperatures of less than about 75 °C, less than about 50°C, or any other suitable temperatures; at atmospheric pressure or under a reduced pressure; as long as the Encukalner is not degraded in its quality. The drying can be carried out for any desired time until the required product quality is achieved. Suitable time for drying can vary from few minutes to several hours for example from about 30 minutes to about 24 or more hours.
[0165] In one embodiment, the present invention provides amorphous solid dispersion of Encukalner having a purity of greater than or equal to 99% w / w.
[0166] In one embodiment, the present invention provides a pharmaceutical composition comprising amorphous solid dispersion of Encukalner with PVP K-30; amorphous solid dispersion of Encukalner with HPMC E5; amorphous solid dispersion of Encukalner with Copovidone; amorphous solid dispersion of Encukalner with Soluplus; or least one pharmaceutically acceptable excipient.
[0167] In one embodiment, the present invention provides a pharmaceutical composition comprising Encukalner crystalline Form-Dl and the pharmaceutically acceptable carrier.In one embodiment, the present invention provides Encukalner crystalline Form-Dl having a purity of greater than 98% or greater than 98.5% or greater than 99% or greater than 99.5% or greater than 99.8%.
[0168] In one embodiment, the present application provides the Encukalner crystalline Form-Dl which is an anhydrous crystalline form.
[0169] DEFINITIONS
[0170] The following definitions are used in connection with the present invention unless the context indicates otherwise. The term “amorphous” refers to a solid lacking any long-range translational orientation symmetry that characterizes crystalline structures although; it may have short range molecular order similar to a crystalline solid.
[0171] The term "about" when used in the present application preceding a number and referring to it, is meant to designate any value which lies within the range of ±10%, preferably within a range of ±5%, more preferably within a range of ±2%, still more preferably within a range of ±1 % of its value. For example, "about 10" should be construed as meaning within the range of 9 to 11, preferably within the range of 9.5 to 10.5, more preferably within the range of 9.8 to 10.2, and still more preferably within the range of 9.9 to 10.1.
[0172] Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Reasonable variations of the described procedures are intended to be within the scope of the present invention. While particular aspects of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.EXAMPLES
[0173] Example-1: Preparation of amorphous solid dispersion of Encukalner with PVP K-30 (1:4 w / w)
[0174] To Encukalner (0.5 g) was added Methanol: Acetone (1:1) ratio and then reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution. To the above reaction mixture was added PVP K-30 (2g). The reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution & then filtered and spray dried at 65 °C to get solid. The solid obtained was dried for 12 hours to obtain the title compound. PXRD pattern is shown in Figure 1.
[0175] Example-2: Preparation of amorphous solid dispersion of Encukalner with HPMC E5 (1:4 w / w)
[0176] To Encukalner (0.5 g) was added Methanol: Acetone (1:1) ratio and then reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution. To the above reaction mixture was added HPMC E5 (2g) and DCM (6ml) and the reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution. The above solution was spray dried at 65°C to get solid. The solid obtained was dried for 12 hours to obtain the title compound. PXRD pattern is shown in Figure 2.
[0177] Example-3: Preparation of amorphous solid dispersion of Encukalner with Copovidone (1:4 w / w)
[0178] To Encukalner (0.5 g) was added Methanol: Acetone (1:1) ratio and then reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution. To the above reaction mixture was added Copovidone (2g). The reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution & then filtered and spray dried at 65 °C to get solid. The solid obtained was dried for 12 hours to obtain the title compound. PXRD pattern is shown in Figure 3.
[0179] Example-4: Preparation of amorphous solid dispersion of Encukalner with Soluplus (1:4 w / w)
[0180] To Encukalner (0.5 g) was added Methanol: Acetone (1:1) ratio and then reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution. To the above reactionmixture was added Soluplus (2g). The reaction mixture was stirred for 5-10 min at room temperature to obtain clear solution & then filtered and spray dried at 65 °C to get solid. The solid obtained was dried for 12 hours to obtain the title compound. PXRD pattern is shown in Figure 4.
[0181] Example-5: Preparation of anhydrous crystalline Form-Dl of Encukalner
[0182] To a Encukalner (200 mg) was added Toluene (8 ml). The reaction mixture was stirred for 10-15 min at 85 °C to obtain clear solution. The resultant clear solution was slowly cooled to 30 °C and filtered to get solid material. The solid material obtained was dried for 23 hours to obtain the title compound. PXRD pattern is shown in Figure 5.
[0183] Example-6: Preparation of anhydrous crystalline Form-Dl of Encukalner
[0184] To a Encukalner (10 g) was added Toluene (350 ml). The reaction mixture was stirred for 10-15 min at 80°C to obtain clear solution. The resultant clear solution was slowly cooled to 25 °C for 1-2 hrs and filtered to get solid material. The solid material obtained was dried for 20 hours at 80°C to obtain the title compound. PXRD pattern is shown in Figure 5.
[0185] Yield (%): 80.0%
Claims
CLAIMS1. A crystalline Form-Dl of Encukalner characterized by powder X-ray diffraction PXRD pattern comprising at least one or more characteristic peaks selected from 5.64, 6.73, 7.08, 10.38, 11.19, 11.51, 13.57, 14.91, 15.45, 16.48, 18.79, 19.99, 20.46 and 21.89 ±0.2° 20.
2. The crystalline Form-Dl of claim 1, wherein crystalline form Form-Dl, further characterized by PXRD pattern comprising peaks selected from 9.33, 12.19, 12.87, 14.39, 15.3, 17.35, 18.17, 19.07, 20.74, 21.11, 22.56, 23.4, 23.78, 25.44, 25.75 and 27.35± 0.2° 20.
3. The crystalline Form-Dl of claim 1 and claim 2, wherein PXRD pattern substantially corresponds to the PXRD diffractogram shown in Figure 5.
4. The crystalline Form-Dl of claim 1 is characterized by a differential scanning calorimetry thermogram wherein the differential scanning calorimetry thermogram of crystalline Form-Dl comprises an endothermic peak at a temperature of 188 ±2 °C and endothermic onset temperature at 185 ±2 °C.
5. The crystalline Form-Dl of claim 4, wherein the differential scanning calorimetry thermogram of crystalline Form-Dl is substantially as shown in Figure 6.
6. The crystalline Form-Dl of claim 1 is characterized by a thermogravimetric analysis curve wherein the thermogravimetric analysis curve of crystalline Form-Dl shows a weight loss of about 1.05 % up to 200 °C.
7. The crystalline Form-Dl of claim 6, wherein the thermogravimetric analysis curve of crystalline Form-Dl is substantially as shown in Figure 7.
8. The crystalline Form-Dl of claim 1 is characterized by a Dynamic vapour sorption (DVS) wherein the Dynamic vapour sorption (DVS) analysis indicates a weight change of not more than 0.1% at 80% RH.
9. The crystalline Form-Dl of claim 8, wherein the Dynamic vapour sorption (DVS) of crystalline Form-Dl substantially as illustrated in Figure 8.
10. The crystalline Form-Dl of claim 1 is characterized by a Fourier Transform Infrared (FTIR) spectrum comprising absorption peaks at 2828, 859, 829, 821, 802, 730, 710, 533, 472, and 453 ±5 cm-1.
11. The crystalline Form-Dl of claim 10, wherein the Fourier Transform Infrared (FTIR) spectrum overlay is substantially as illustrated in Figure 10.
12. The anhydrous crystalline Form-Dl of claim 1 is characterized by a Raman spectrum comprising peak positions at 211, 235, 969, 1030, 1237, 1263, 1298, 2904, 2920, 3053 and 3868±5 cm1.
13. The anhydrous crystalline Form-Dl of claim 12, wherein the Raman spectrum overlay is substantially as illustrated in Figure 11.
14. Process for preparing the crystalline Form-Dl of Encukalner, comprising;a) Providing a solution of Encukalner in a suitable solvent;b) Stirring at about 60 °C to 80 °Cc) cooling and isolating the crystalline Form-Dl15. Process for preparing crystalline Form-Dl of Encukalner as claimed in claim 14, wherein in suitable solvent in step a) is selected from esters, ethers, hydrocarbon solvents or mixture thereof.
16. Process for preparing crystalline Form-Dl of Encukalner as claimed in claim 15, wherein solvent is selected from hexane, heptane, toluene, xylene, ethylbenzene and / or mixture thereof.
17. Process for preparing crystalline Form-Dl of Encukalner as claimed in claim 14, wherein in step c) the mixture is cooled to a temperature of 25 °C to 30°C.
18. Process for preparing anhydrous crystalline Form-Dl of Encukalner as claimed in claim 14, wherein obtained a stable crystalline polymorphic form-Dl has purity greater than 99%.
19. Pharmaceutical composition comprising crystalline Form-Dl of Encukalner as claimed in claim 1-18 and at least one pharmaceutically acceptable carrier.
20. Use of a crystalline Form-Dl of Encukalner, as defined in any one of claims 1 to 19, for the manufacture of a pharmaceutical medicament for treating or preventing a neurological disorder, wherein the neurological disorder is selected from refractory focal onset seizures and major depressive disorder.
21. An amorphous solid dispersion of Encukalner, comprising Encukalner and at least one pharmaceutically acceptable excipient or carrier, wherein the excipient or carrier is selected from hydroxypropylmethylcellulose (HPMC E5), polyvinylpyrrolidone (PVP K-30), copovidone, Soluplus, wherein the amorphous solid dispersion is characterized by a powder X-ray diffraction (PXRD) pattern substantially as illustrated in Figure 1 to 4.
